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Thegutmicroﬂoraisanimportantconstituentintheintestinalmucosalbarrierandhasbeenintroducedastheconceptofprobiotic
therapy that beneﬁcially aﬀects the host by improving its intestinal microbial balance. Therefore, the main objective of the study
was to explore the protective potential of various lactobacilli strains for murine giardiasis. By experimentation, it was found that
the probiotic supplementation of either Lactobacillus casei, L. acidophilus, L. plantarum,o rL. rhamnosus GG, 7 days prior to
inoculation with G. lamblia trophozoites, reduced the rate of cyst excretion compared with Giardia-infected mice. Interestingly,
L. GG was found to be the most eﬀective probiotic in reducing the duration of giardia cycle and acts as an eﬀective prophylactic
probiotic for murine giardiasis but needs to be clinically correlated due to entirely diﬀerent human microﬂora.
1.Introduction
The zoonotic intestinal disease giardiasis is caused by the
enteric protozoan parasite Giardia lamblia, one of the most
common causes of intestinal infections worldwide. Infection
with Giardia is acquired by the ingestion of viable cysts
due to inadequate sanitation or poor treatment of drinking
water. Giardiasis is a disease of main concern as it aﬀects
children, adults, hypogammaglobulineamic, malnourished,
and immunocompromised individuals leading to either
acute or chronic diarrhea, nausea, malabsorption, weight
loss, steatorrhoea, and growth retardation particularly in
youngchildren [1–3].Theﬁrstlineoftreatmentforgiardiasis
is antibiotic like nitroimidazoles and nitrofurans. However,
antibiotic therapy is associated with many unpleasant side
eﬀects (e.g., metallic taste), poor patient compliance, and
enhanced occurrence of resistance leading to subsequent
treatment failure. Thus, this has encouraged research on al-
ternative biotherapeutic strategies such as plant extracts
(phytomedicine),productsderivedfrombees,andprobiotics
that are safe, inexpensive, and eﬀective in improving the
cause of intestinal parasitosis [4–6].
Normally, the generation of immunophysiologic regu-
lation in the gut depends on the establishment of indige-
nous microﬂora and has led to the introduction of novel
therapeutic interventions based on the consumption of cul-
tures of beneﬁcial live microorganisms, the probiotics [7].
Probioticsare livemicroorganisms thatbeneﬁcially aﬀectthe
gastrointestinal balanceifingestedinsuﬃcientnumbers, and
provide health beneﬁts that go beyond normal nutritional
eﬀects [8]. Probiotics, also known as microbial interference
therapy (MIT), oﬀer an attractive supportive therapy for
gastrointestinal infections by acting as surrogative normal
ﬂora via various mechanisms such as production of antimi-
crobial substances, modiﬁcation of toxins, interference with
attachment,stimulation ofimmunesystemoracombination
of mechanisms [9, 10]. In our earlier studies, we have ob-
served that the probiotics L. casei and L. acidophilus both
modulate the murine giardiasis by reducing the severity and
duration of the disease [11–13]. However, it has also been
observed that diﬀerent strains of lactic acid bacteria (LAB)
have diﬀerent properties and may beneﬁcially inﬂuence
the composition and metabolic activity of the endogenous
microbiota [7, 14] or inhibit the growth of a wide range of
enteropathogens in intestinal diseases [15], as not all the
strains are able to adequately survive the acidic pH or to
adhere and colonize the gut. Moreover, till date no eﬀective
probiotic has been reported for giardiasis, thus it is pertinent
to delineate an eﬀective probiotic for giardiasis.2 Interdisciplinary Perspectives on Infectious Diseases
2.Methods
2.1.Parasite and CultureConditions. Giardia lambliatropho-
zoites (Portland strain I) were grown axenically in TYI-S-33
medium supplemented with antibiotic solution, and pH was
adjusted to 6.9 before sterilization with 0.22µms e i t zﬁ l t e r .
For experimental inoculation, actively growing trophozoites
(48–72holdculture)weresedimentedafterchillingthetubes
in ice for 15min and ﬁnally suspended in phosphate buﬀer
saline (PBS-7.2) to contain 1×106 trophozoites/0.1mL [12].
2.2. Bacterial Strains, Preparation, and Inoculation. Various
lactobacilli strains (Lactobacillus GG, L. acidophilus, L. plan-
tarum,andL. casei) were procured from Microbial Type Cul-
ture Collection (MTCC), Institute of Microbial Technology
(IMTECH), Chandigarh, India. These lactobacilli strains
w e r eg r o w ni nM R Sm e d i u mf o r1 8h o u r s .T h e r e a f t e r ,t h e
cultures were centrifuged, washed, and suspended in PBS-
7.2 to contain 1 × 109 lactobacilli/0.1mL and were fed via
orogastric gavage [12].
2.3. Animals. BALB/c mice aged 5-6 weeks old (18–20gm)
were obtained from Central Animal House, Panjab Univer-
sity, Chandigarh, India. These were housed under standard
conditions of light and dark cycle and were fed with
laboratory diet and water ad libitum. Water and feed
before supplementation to animals were monitored for any
bacterial or parasitic contamination by Gram’s staining and
Lugol’s iodine staining techniques [16]. Animals were also
screened for Giardia infection via simple microscopic stool
examination for three consecutive days. Only Giardia-free
mice were employed. Care and use of animals were in
accordance with the guidelines of the institutional ethical
committee.
2.4. Experimental Design and Followup of the Animals.
Animals were divided mainly into ﬁve groups. Each group
comprised of 6 animals. Group I (Giardia infected): these
mice were challenged orally with a single dose of 1 ×
106 Giardia trophozoites via orogastric gavage. Group II (L.
casei-Giardia); Group III (L. acidophilus- Giardia); Group
IV (L. plantarum-Giardia); Group V (L. rhamnosus GG-
Giardia). Animals belonging to Groups II, III, IV, and V
were fed orally with a single dose of respective lactobacilli
strains (1 × 109 lactobacilli/0.1mL) for 7 days. On the 8th
day, a single challenge dose of Giardia trophozoites (1 × 106
trophozoites) was given orally along with a single dose of
probiotic treatment. The probiotic treatment was further
continued for 25 days [11]. After respective treatments in all
the groups, Giardia cyst count was monitored. Lactobacilli
and trophozoite counts were monitored only with the most
eﬀective probiotics.
2.5. Giardia Cysts in Faeces. Brieﬂy, one gram of freshly
passedfaecalsampleswasdissolvedin10mLofnormalsaline
and homogenized using pestle and mortar mixer. Slide was
prepared, and cysts stained with iodine were counted on
everythirddayusingahemocytometerandwereexpressedas
cysts mL−1 [11].
2.6. Lactobacilli in Faeces with L. GG. To conﬁrm if the lacto-
bacilli species were able to survive the stress and colo-
nize within the gastrointestinal tract, freshly voided fae-
cal samples of mice belonging to Groups I and V were
homogenized in normal saline and serially diluted. The
diluted homogenates (0.1mL) were spread plated on MRS
agar and incubated at 37◦C for 24–48hrs, and CFU were
counted [11].
2.7.Giardia Trophozoitesin theSmallIntestine (Jejunum)with
L.GGastheProbiotic. Miceweresacriﬁced,andtheproximal
10cm section, mainly the jejunum, was removed and placed
in 5mL of the ice-chilled isotonic saline solution. The small
intestine sections were minced and kept for 15–20 minutes
in ice-chilled saline, and trophozoites were counted using
a haemocytometer. Mice with no detectable trophozoites
were considered to have cleared the parasite infection [12].
2.8. Statistical Analysis. Results were expressed as mean ±
SD. The inter-group variation was assessed by student’s
t-test and one way analysis of variance (ANOVA) with
equal number of observations followed by Tukey’s multiple
comparison test. Statistical signiﬁcance of the result was cal-
culated at P<. 05.
3.Results
3.1. Giardia Cycle. Giardia-infected mice (Group I) voided
cystsgraduallyfromday1onwardsandwassigniﬁcantly(P<
.05) highest (306.4 × 104 ± 10.63) on day 7 postinoculation
(PI). Thereafter, the cyst count started decreasing, and mice
became Giardia-free by day 25 PI (Figure 1). However, oral
feeding either with L. acidophilus, L. plantarum, L. casei, L.
acidophilus,o rL. GG signiﬁcantly (P<. 05) reduced the
cyst excretion in mice belonging to all the groups (II, III,
IV, and V) from the beginning and became Giardia-free by
days 17 PI (Groups II and III) and 13 PI (Groups IV and V),
respectively. Interestingly, mice fed orally with L. GG (Group
V) showed signiﬁcantly (P<. 05) least cyst count from
the beginning of the infection (i.e., 5 days PI onwards) and
became Giardia-free by day 13 PI (Figure 1). However, none
o ft h em i c ef r o ma n yo ft h e s eg r o u p ss h o w e da n yc l i n i c a l
symptoms like diarrhea, weight loss, and death.
3.2. Lactobacilli in Faeces with L. GG. The faecal lactobacilli
counts increased signiﬁcantly (P<. 05) in L. GG-Giardia
mice (Group V) from the beginning and were signiﬁcantly
higher (P<. 05) at each point of observation compared with
Giardia-infected mice (Group I) that had least lactobacilli
count (Figure 2).
3.3. Giardia Trophozoitesin the Intestinal Fluid with L. GG. It
was found that oral administration of Giardia trophozoites
resulted in the establishment of infection as assessed by the
number of trophozoites in the jejunum and cyst counts inInterdisciplinary Perspectives on Infectious Diseases 3
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Figure 1: Giardia c y s t si nf a e c e so fm i c eb e l o n g i n gt od i ﬀerent
groups. Values are mean ± SD, ∗P<. 05 versus Giardia.
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Figure 2: Lactobacilli count (log10 CFU/mL) in faeces. Values are
mean ± SD, ∗P<. 05 versus Giardia.
faeces. Interestingly, trophozoite counts were signiﬁcantly
(P<. 05) reduced in the gut of L. GG-treated mice (Group
V)comparedwith Giardia-infected mice(GroupI,Figure 3).
4.Discussion
Giardiasis is a diarrheal disease mainly of young children
and immunosuppressed or malnourished individuals. It is
generally accepted that the enteric bacterial environment
represents a physiological factor that can interfere with the
processofaG.lamblia infection.Therefore, thepresentstudy
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Figure 3: Giardia trophozoites count in the small intestine. Values
are mean ± SD, ∗P<. 05 versus Giardia.
was designed to assess the eﬀect of various probiotic supple-
mentations in modulating the Giardia cycle in BALB/c mice.
It was found that orally administered Giardia trophozoites
in mice could transiently colonize the gut, and infection was
self-limiting. It is very well evident that the supplementation
of various probiotics has the potential to modulate murine
giardiasis to variable extent. Amongst all the lactobacilli, L.
GG was found to be the most eﬀective probiotic in modulat-
ing the giardiasis, both in terms of duration of Giardia cycle
andrateofcystexcretion.Thepresentobservationofreduced
cyst count may be either due to better survival of L. GG in
stomach or eﬀective adherence and colonization in the gut
compared with other lactobacilli strains [17]. Moreover, L.
GG has also been found to be an eﬀective treatment therapy
for various bacterial and viral diarrheal diseases and is in
accordance with the earlier studies [8, 11–13].
The ability of the L. GG to adhere to gastrointestinal
tract and persistence was further evaluated by monitoring
the lactobacilli count in faeces. It was observed that mice fed
with L. GG had more lactobacilli in faeces compared with
Giardia-infected mice alone. Interestingly, it was also found
that L. GG feeding reduced the active number of Giardia
trophozoites in the gut leading to early resolution of Giardia
infection by day 13 (PI). This may again be suggestive of
eﬀective colonizing ability of L. GG and interaction with
enterocytes, thus enriching the endogenous microbiota and
isin accordancewithearlier studies[11, 18–20].The reduced
durationofinfectionmaybepartlyeitherduetoeﬀectivecol-
onization of lactobacilli, production of secretary substance
or competition for nutrients, and so forth. However, the
modiﬁcation of other key intestinal components remains to
be screened.
Taken together, it can be concluded that various lac-
tobacilli species have variable eﬀects in intestinal diseases.
Among the four lactobacilli species, L. GG was found to be
the most eﬀective probiotics for murine giardiasis. Thus it
can be said that L. GG is the ideal, safe, and stronger barrier4 Interdisciplinary Perspectives on Infectious Diseases
against intestinal pathogens than other lactobacilli strains,
leading to improved core health, that is, healthier digestion
and improved immune system, and it may also serve as an
a l t e r n a t i v em o d ef o rt h ep r e v e n t i o no fg i a r d i a s i s .
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